WallStSmart

Aclarion Inc (ACON)vsHealthEquity Inc (HQY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HealthEquity Inc generates 1625927% more annual revenue ($1.36B vs $83,770). HQY leads profitability with a 17.4% profit margin vs 0.0%. HQY earns a higher WallStSmart Score of 62/100 (C+).

ACON

Avoid

33

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 6.8
Piotroski: 3/9Altman Z: 2.48

HQY

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 7.5Value: 6.7Quality: 7.5
Piotroski: 7/9Altman Z: 1.86
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACON.

HQYUndervalued (+58.3%)

Margin of Safety

+58.3%

Fair Value

$184.63

Current Price

$95.14

$89.49 discount

UndervaluedFair: $184.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACON2 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
30.5%10/10

Revenue surging 30.5% year-over-year

HQY1 strengths · Avg: 8.0/10
Operating MarginProfitability
28.4%8/10

Strong operational efficiency at 28.4%

Areas to Watch

ACON4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.98M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

HQY2 concerns · Avg: 4.0/10
P/E RatioValuation
33.7x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.864/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ACON

The strongest argument for ACON centers on Price/Book, Revenue Growth. Revenue growth of 30.5% demonstrates continued momentum.

Bull Case : HQY

The strongest argument for HQY centers on Operating Margin. Profitability is solid with margins at 17.4% and operating margin at 28.4%. PEG of 1.40 suggests the stock is reasonably priced for its growth.

Bear Case : ACON

The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.

Bear Case : HQY

The primary concerns for HQY are P/E Ratio, Altman Z-Score.

Key Dynamics to Monitor

ACON profiles as a hypergrowth stock while HQY is a mature play — different risk/reward profiles.

ACON carries more volatility with a beta of 1.24 — expect wider price swings.

ACON is growing revenue faster at 30.5% — sustainability is the question.

HQY generates stronger free cash flow (135M), providing more financial flexibility.

Bottom Line

HQY scores higher overall (62/100 vs 33/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aclarion Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Aclarion Inc (ACON) is a pioneering healthcare technology firm dedicated to advancing non-invasive diagnostic solutions for musculoskeletal conditions through cutting-edge imaging and data analytics. By harnessing the power of machine learning, Aclarion empowers healthcare providers with actionable insights that not only improve clinical outcomes but also optimize treatment pathways and reduce costs. Positioned at the forefront of the digital health revolution, the company is well-equipped to meet the rising demand for effective diagnostics, thereby significantly enhancing patient management and care standards in a dynamic healthcare landscape. Aclarion's commitment to improving patient care underscores its vital role in the future of healthcare delivery.

Visit Website →

HealthEquity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

HealthEquity, Inc. provides technology-enabled service platforms to consumers and employers in the United States. The company is headquartered in Draper, Utah.

Want to dig deeper into these stocks?